Newsletter | February 19, 2021

02.19.21 -- Orphan Drugs, Pricing, And Reputation Risk

Featured Articles
I Picked A Heck Of A Time …

A new CEO’s observations on managing a fast-growing, fully integrated biopharmaceutical company from the other side of the world during a global pandemic.

Thrust Into A New Fundraising Norm

Gone — for a while, anyway — are the days of pressing the flesh and pounding the pavement with your pitch deck. Here’s how one successful biotech startup is maintaining its conduit to cash.

COVID-19’s Impact On Outsourced Manufacturing

To understand how the pandemic impacted outsourced manufacturing, ISR included a few questions on the topic in its annual contract manufacturing benchmarking surveys.

Web-Exclusive Content
Orphan Drugs, Pricing, And Reputation Risk

Mitigating the risk of high-priced launches requires an enhanced approach beyond brand marketing, for which many companies are not prepared.

025: Are Decentralized Trials Finally Here To Stay?

Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways? Our guest, editor, Ed Miseta, weighs in on this timely topic.

February 2021 Digital Edition

Inside you will find more on:

  • Talking With The Cofounders Of Appolomics
  • Artificial Intelligence In Drug Development
  • Leadership Lessons
  • CEO Corner

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.